BIOASIS TECHNOLOGIES announced the following amendments to the terms of the previously announcement arrangement agreement with Midatech Pharma: Midatech is no longer required to seek delisting from AIM following completion of the arrangement; and the $750,000 bridge loan to be provided by Midatech to Bioasis will now be advanced in three equal tranches of $250,000 instead of the entire amount being advanced immediately, as previously contemplated.
Published first on TheFly
